We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.88%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.74B
AUM Growth
+$366M
Cap. Flow
+$279M
Cap. Flow %
10.2%
Top 10 Hldgs %
49.25%
Holding
82
New
4
Increased
18
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$84.9M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$63.4M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$54M
4
RVMD icon
Revolution Medicines
RVMD
+$41.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$41.1M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$47.6M
2
CGEM icon
Cullinan Oncology
CGEM
+$47.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$34.3M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$21.2M
5
ANNX icon
Annexon
ANNX
+$19.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLN
51
Silence Therapeutics
SLN
$525M
$9.35M 0.34%
1,508,416
– –
CDTX
52
DELISTED
Cidara Therapeutics
CDTX
$8.71M 0.32%
343,056
– –
NCEL
53
NewcelX Ltd
NCEL
$18.7M
$8.68M 0.32%
14,368
– –
VSTM icon
54
Verastem
VSTM
$489M
$7.9M 0.29%
1,585,221
– –
ALPN
55
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.63M 0.24%
858,339
-277,601
-24% -$2.21M
VIRX
56
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.75M 0.21%
3,614,662
– –
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$259M
$5.49M 0.2%
2,326,710
– –
PVLA
58
Palvella Therapeutics
PVLA
$2.02B
$4.96M 0.18%
63,504
– –
ELEV
59
DELISTED
Elevation Oncology
ELEV
$4.39M 0.16%
2,312,200
– –
VRDN icon
60
Viridian Therapeutics
VRDN
$2.09B
$4.27M 0.16%
168,000
-1,070,974
-86% -$34.3M
HLVX
61
DELISTED
HilleVax
HLVX
$4.11M 0.15%
248,579
– –
MOLN
62
Molecular Partners
MOLN
$2.66M 0.1%
443,221
– –
IVA
63
Inventiva
IVA
$1.04B
$2.5M 0.09%
686,040
– –
WHWK
64
Whitehawk Therapeutics
WHWK
$190M
$2.3M 0.08%
318,205
-244,104
-43% -$2.61M
MTEM
65
DELISTED
Molecular Templates, Inc.
MTEM
$1.9M 0.07%
333,104
– –
IMUX icon
66
Immunic
IMUX
$187M
$1.71M 0.06%
114,943
– –
CRVS icon
67
Corvus Pharmaceuticals
CRVS
$1.1B
$1.25M 0.05%
1,370,947
– –
INFI
68
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.02M 0.04%
6,353,645
– –
ELTX icon
69
Elicio Therapeutics
ELTX
$73.8M
$621K 0.02%
107,130
– –
GLMD icon
70
Galmed Pharmaceuticals
GLMD
$4.82M
$575K 0.02%
7,488
-2,177
-23% -$234K
RZLT icon
71
Rezolute
RZLT
$445M
$366K 0.01%
190,815
– –
NEUP
72
Neuphoria Therapeutics
NEUP
$21.2M
$211K 0.01%
6,748
– –
ANNX icon
73
Annexon
ANNX
$826M
– –
-3,780,694
Closed -$19.5M
COGT icon
74
Cogent Biosciences
COGT
$6.69B
– –
-984,824
Closed -$11.4M
GBIO
75
DELISTED
Generation Bio
GBIO
– –
-10,290
Closed -$404K
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2023 Portfolio in Review

As of Q1 2023, BVF Inc held 82 positions worth $2.74B, up 15% from $2.37B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

BVF Inc deployed $279M of net new capital in Q1 2023, opening 4 new positions and adding to 18 existing holdings. Its largest new stake was Protagonist Therapeutics: 3,775,900 shares worth $86.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $47.5M trimmed.

  • BVF Inc's largest Q1 2023 buy was Protagonist Therapeutics: 3,775,900 shares worth $86.8M.
  • BVF Inc added most to Lakefront Biotherapeutics American Depositary Shares in Q1 2023, an estimated $84.9M increase.
  • BVF Inc's biggest Q1 2023 reduction was Cullinan Oncology, cutting an estimated $47.5M.
  • BVF Inc fully exited Arcus Biosciences in Q1 2023, selling an estimated $47.6M.
  • BVF Inc's ten largest holdings make up 49% of its $2.74B portfolio in Q1 2023.
  • BVF Inc opened 4 new positions and closed 10 in Q1 2023.
  • BVF Inc's portfolio value rose 15% quarter-over-quarter to $2.74B.

Based on BVF Inc's 13F filing for Q1 2023, filed 15 May 2023.